ηγωεϊ εδεγςεϊ μςιϊεπεϊ
θας ξγεεηϊ ςμ δϊεφΰεϊ μψαςεο δψαιςι ωμ 2007 εμωπϊ 2007δηαψδ ϊρτχ ϊηζιϊ μωπϊ 2008 ε-2009 αωιηϊ εςιγδ μωεχ δδεο αωςδ 15:30 δηαψδ ξςμδ ΰϊ δγιαιγπγ δψαςεπι
12/2/2007 θας ϊςωιεϊ τψξφαθιεϊ ας"ξ γιεεηδ διεν ςμ ϊεφΰεϊ δψαςεο δψαιςι ωμ 2007 εδωπδ λεμδ ωδρϊιιξε α 31 αγφξαψ, 2007.
ςχψι δϊεφΰεϊ
ξλιψεϊ ωιΰ μωπδ εμψαςεο ωμ 9.4 ξιμιΰψγ γεμψ ε-2.6 ξιμιΰψγ γεμψ, αδϊΰξδ.
δϊεφΰεϊ δξωχτεϊ ςμιιδ ωμ 12 ΰηεζ ε-13 ΰηεζ, αδϊΰξδ, αδωεεΰδ μϊχετδ δξχαιμδ ΰωϊχγ.
ωιΰ αψεεη πχι εψεεη μξπιδ μωπδ ωμ 1,952 ξιμιεο γεμψ ε-2.38 γεμψ, αδϊΰξδ. ςμ τι λμμι ηωαεπΰεϊ ξχεαμιν αΰψδ"α (US GAAP), δψεεη δπχι ωμ ωπϊ 2007 εδψεεη μξπιδ βγμε αιεϊψ ξτι 3. αδωεεΰδ μϊεφΰεϊ δξϊεΰξεϊ ωμ ωπϊ 2006, δψεεη δπχι ωμ ωπϊ 2007 βγμ α-5 ΰηεζ εδψεεη μξπιδ βγμ α-3 ΰηεζ.
ψεεη πχι εψεεη μξπιδ μψαςεο δψαιςι ωμ 570 ξιμιεο γεμψ ε-0.69 γεμψ, αδϊΰξδ. ςμ τι λμμι ηωαεπΰεϊ ξχεαμιν αΰψδ"α (US GAAP), δψεεη δπχι μωπϊ 2007 εδψεεη μξπιδ βγμε α-24 ΰηεζ ε-23 ΰηεζ, αδϊΰξδ. αδωεεΰδ μϊεφΰεϊ δξϊεΰξεϊ αψαςεο δψαιςι αωπϊ 2006 , δψεεη δπχι μψαςεο βγμ α-32 ΰηεζ εδψεεη μξπιδ βγμ α- 30 ΰηεζ.
ωιΰ αξλιψεϊ βμεαμιεϊ ωμ χετχρεο (αξεπηι ξηιψ ξλιψδ μωεχ) μωπδ λεμδ; δξλιψεϊ δρϊλξε αωπϊ 2007 α-1,713 ξιμιεο γεμψ; ξλιψεϊ χετχρεο αΰψδ"α ηφε ΰϊ χε δξιμιΰψγ γεμψ εδρϊλξε α-1,094 ξιμιεο γεμψ
ωμξδ ιπΰι, πωιΰ εξπλ"μ θας, φιιο, "2007 διιϊδ ωπδ ξφειπϊ μθας. ωπδ ωαδ δωβπε ϊεφΰεϊ ωιΰ αλμ ϊηεξι δτςιμεϊ ωμπε εηιζχπε ΰϊ ξεαιμεϊ δωεχ ωμπε αωεεχι ξτϊη. διωβι ωπϊ 2006 δφιαε ατπιπε ΰϊβψ ξωξςεϊι εΰπι ωξη ωϊεφΰεϊ ωπϊ 2007 θεαεϊ ΰσ ιεϊψ ξδιςγιν δΰϊβψιιν ωδφαπε μςφξπε αωπδ ζε."
ξψ ιπΰι δερισ, "δϊεφΰεϊ ξαθΰεϊ αΰετο δαψεψ αιεϊψ ΰϊ ιλεμεϊιδ δξιεηγεϊ ωμ θας, εδο ΰμδ ωιΰτωψε μπε μδξωικ ΰϊ ξρεψϊ δφξιηδ ειφιψϊ ςψκ μαςμι δξπιεϊ ωμπε. ΰπι ξφτδ ωϊπετϊ δφξιηδ ωμ 2007 ϊξωκ βν α- 2008 εϊεαιμ ΰεϊπε μωπδ ξφειπϊ περτϊ μθας."
ξλιψεϊ αψαςεο δψαιςι ωμ 2007 ςμε α-13 ΰηεζ εδρϊλξε α-2,576 ξιμιεο γεμψ, αδωεεΰδ μ-2,277 ξιμιεο γεμψ αψαςεο δψαιςι ωμ 2006. δξλιψεϊ μωπϊ 2007 δρϊλξε α-9.4 ξιμιΰψγ γεμψ, βιγεμ ωμ 12 ΰηεζ αδωεεΰδ μωπϊ 2006.
δψεεη δπχι μψαςεο δψαιςι δρϊλν α-570 ξιμιεο γεμψ, βιγεμ ωμ 24 ΰηεζ αδωεεΰδ μψεεη πχι ςμ τι λμμι ηωαεπΰεϊ ξχεαμιν αΰψδ"α (US GAAP) ωμ 460 ξιμιεο γεμψ αψαςεο δψαιςι ωμ 2006. δψεεη μξπιδ αγιμεμ ξμΰ βγμ α-23 ΰηεζ μ-0.69 γεμψ.
δψεεη δπχι μωπϊ 2007, δρϊλν α-1,952 ξιμιεο γεμψ αδωεεΰδ μ-546 ξιμιεο γεμψ α-2006, ςμ τι λμμι ηωαεπΰεϊ ξχεαμιν αΰψδ"α (US GAAP). δψεεη μξπιδ αγιμεμ ξμΰ δρϊλν α-2.38 γεμψ αδωεεΰδ μ-0.69 γεμψ μξπιδ α-2006.
δψεεη δπχι εδψεεη μξπιδ μψαςεο δψαιςι ωμ 2006 λεμμιν δϊΰξεϊ ωμ πιλει δλπρεϊ δχωεψεϊ αξρ εηιεαιν ΰηψιν εδρϊλξε αδχθπϊ δλπρδ αρλεν ωμ 27 ξιμιεο γεμψ. ςαεψ ωπϊ 2006, δψεεη δπχι εδψεεη μξπιδ δξεϊΰξιν λεμμιν ξηιχεϊ ωμ δεφΰεϊ δχωεψεϊ μψλιωϊ Ivax (αςιχψ in process R&D) αρλεν ωμ 1,321 ξιμιεο γεμψ. πϊεπιν ξεϊΰξιν ΰμε ΰιπν ςμ-τι λμμι δηωαεπΰεϊ δξχεαμιν αΰψδ"α (US GAAP). θας ξΰξιπδ, ςν ζΰϊ, λι δωιξεω απϊεπιν δξεϊΰξιν, ξριις μδαπδ θεαδ ιεϊψ ωμ δξωχιςιν ΰϊ ξβξεϊ δςρχιν ωμ δηαψδ. αωπϊ 2007 μΰ πςωε δϊΰξεϊ εϊεφΰεϊ 2007 ξεφβιν ψχ ςμ τι λμμι δηωαεπΰεϊ δξχεαμιν αΰψδ"α (US GAAP).
δψεεη δπχι μψαςεο δψαιςι ωμ 2007 φξη α-32 ΰηεζ μ-570 ξιμιεο γεμψ, αδωεεΰδ μ-433 ξιμιεο γεμψ αϊχετδ δξχαιμδ α-2006. δψεεη μξπιδ αγιμεμ ξμΰ βγμ α-30 ΰηεζ μ-0.69 γεμψ ξ-0.53 γεμψ.
δψεεη δπχι μωπϊ 2007 δρϊλν α-1,952 ξιμιεο γεμψ, ςμιιδ ωμ 5 ΰηεζ ξ-1,867 ξιμιεο γεμψ α-2006. δψεεη μξπιδ αγιμεμ ξμΰ δρϊλν α-2.38 γεμψ, ςμιιδ ωμ 3 ΰηεζ ξ-2.30 γεμψ α-2006.
ωιπειιν αωςψι ημιτιο ωπαςε ξιψιγϊ ςψκ δγεμψ δΰξψιχΰι ϊψξε λ-4 ΰηεζ μξλιψεϊ δηαψδ ξηευ μΰψδ"α (αιιηεγ αΰιψετδ εαωεεχιν αιπμΰεξιιν) αψαςεο δψαιςι λξε βν μλμ ωπϊ 2007. αξχαιμ, πψωξδ βν ςμιδ αδεφΰεϊ αωμ ϊπεγεϊ ωςψι δημιτιο λκ ωαριλεν δωτςϊν ςμ δψεεη δϊτςεμι εδπχι διιϊδ ωεμιϊ.
δξλιψεϊ δτψξφαθιεϊ αφτεο ΰξψιχδ (λεμμ χετχρεο®) αψαςεο δψαιςι, ΰωψ διεε 59 ΰηεζ ξρκ δξλιψεϊ δτψξφαθιεϊ, δρϊλξε α- 1,435 ξιμιεο γεμψ αδωεεΰδ μ-1,252 ξιμιεο γεμψ αψαςεο δψαιςι ωμ ωπϊ 2006, βιγεμ ωμ 15 ΰηεζ. δξλιψεϊ δψαςεπιεϊ δεωτςε μθεαδ ξδδωχδ ωμ Pantoprazole, λξε βν δξωκ ξλιψεϊ ωμ ξεφψιν βπψιιν λξε Oxycodone, Amlodipine/Benazapril ε-Famciclovier. απερσ, βγμε ξλιψεϊ ξεφψι δπωιξδ, λξε βν ξλιψεϊ χετχρεο® εΰζιμχθ®.
αωπϊ 2007, δξλιψεϊ δτψξφαθιεϊ αφτεο ΰξψιχδ δβιςε μωιΰ ωμ 5,162 ξιμιεο γεμψ, βιγεμ ωμ 8 ΰηεζ αδωεεΰδ μ-2006, μξψεϊ ωα-2006 θας δωιχδ ααμςγιεϊ ωμεωδ ξδξεφψιν δβγεμιν αϊςωιιδ δβπψιϊ. αωπδ λεμδ, δξλιψεϊ αφτεο ΰξψιχδ δεωτςε μθεαδ ξξβξεϊ γεξεϊ μΰμδ αψαςεο δψαιςι ςν ξλιψεϊ βπψιεϊ ηζχεϊ, απερσ μβιγεμ αξλιψεϊ ξεφψι δπωιξδ, χετχρεο® εΰζιμχθ®.
πλεο μ-7 αταψεΰψ, 2008, μθας ιω 160 αχωεϊ δξξϊιπεϊ μΰιωεψ ρετι ωμ ψωεϊ δξζεο εδϊψετεϊ δΰξψιχΰιϊ (FDA). ρκ δξλιψεϊ δωπϊιεϊ ωμ αχωεϊ ΰμδ, αξεπηι ξλιψεϊ ωπϊιεϊ ωμ δξεφψιν δξχεψιιν αΰψδ"α, διπε λ-101 ξιμιΰψγ γεμψ. θας ξΰξιπδ λι διπδ δψΰωεπδ μδβιω αχωδ μΰιωεψ ςαεψ 49 ξεφψιν ξϊεκ αχωεϊ ΰμδ, δξωχτιν ξλιψεϊ ωπϊιεϊ, αξεπηι ξλιψεϊ ωπϊιεϊ ωμ δξεφψιν δξχεψιιν αΰψδ"α, ωμ ξςμ μ-40 ξιμιΰψγ γεμψ.
ξλιψεϊ τψξφαθιεϊ αΰιψετδ (λεμμ χετχρεο®) αψαςεο δψαιςι, ΰωψ διεε 25 ΰηεζ ξρκ δξλιψεϊ δτψξφαθιεϊ, δρϊλξε α-601 ξιμιεο γεμψ, βιγεμ ωμ 17 ΰηεζ αδωεεΰδ μψαςεο δψαιςι ΰωϊχγ. δβιγεμ αξλιψεϊ πας ξςμιδ αξλιψεϊ δβπψιεϊ (αςιχψ αφψτϊ, ΰιθμιδ, δεμπγ ερτψγ), λξε βν βιγεμ αξλιψεϊ χετχρεο®.
αωπϊ 2007, δξλιψεϊ δτψξφαθιεϊ αΰιψετδ φξηε α-21 ΰηεζ, εδρϊλξε α-2,245 ξιμιεο γεμψ. βιγεμ ζδ πας ξξλιψεϊ βπψιεϊ βαεδεϊ αλμ ΰιψετδ (αξιεηγ ααψιθπιδ, ΰιθμιδ, φψτϊ, ρτψγ εβψξπιδ), ξλιψεϊ βαεδεϊ ωμ ξεφψι πωιξδ (αξιεηγ ααψιθπιδ εφψτϊ), λξε βν ξλιψεϊ χετχρεο® εΰζιμχθ®.
αξδμκ 2007, θας χαμδ 1,160 ΰιωεψιν βπψιιν αΰιψετδ, δξωχτιν 89 ξεμχεμεϊ α-206 τεψξεμφιεϊ. πλεο μ-31 αγφξαψ, 2007, διε μθας 3,166 αχωεϊ μωιεεχ δξξϊιπεϊ μΰιωεψ ρετι α-30 ξγιπεϊ ωεπεϊ αΰιψετδ (λεμμ ξψλζ εξζψη ΰιψετδ), δξωχτεϊ 154 ξεμχεμεϊ α-310 τεψξεμφιεϊ. θας ξΰξιπδ ωφαψ δξεφψιν δξξϊιπιν μΰιωεψ ξςπιχ μθας δζγξπειεϊ μδξωικ ΰϊ δφξιηδ δξδιψδ ωμδ αΰιψετδ.
ξλιψεϊ τψξφαθιεϊ αιπμΰεξιεϊ (λεμμ χετχρεο®) αψαςεο δψαιςι, ΰωψ διεε 16 ΰηεζ ξρκ λμ δξλιψεϊ δτψξφαθιεϊ, φξηε α-11 ΰηεζ μ-400 ξιμιεο γεμψ. δβιγεμ πας αςιχψ ξξλιψεϊ βαεδεϊ αξψλζ εξζψη ΰιψετδ, λξε βν ξλιψεϊ χετχρεο® αΰζεψιν δωεπιν. αψαςεο δψαιςι, ξλιψεϊ θας αΰξψιχδ δμθιπιϊ διεε 6 ΰηεζ ξλμμ δξλιψεϊ δτψξφαθιεϊ, ξψλζ εξζψη ΰιψετδ διεε 5 ΰηεζ ειωψΰμ διεεϊδ 4 ΰηεζ.
μωπϊ 2007, ξλιψεϊ τψξφαθιεϊ αιπμΰεξιεϊ δρϊλξε α-1,440 ξιμιεο γεμψ, βιγεμ ωμ 19 ΰηεζ αδωεεΰδ μ-2006. δβιγεμ πας αςιχψ ξξλιψεϊ βπψιεϊ βαεδεϊ αξψλζ εξζψη ΰιψετδ εΰξψιχδ δμθιπιϊ, λξε βν βιγεμ αξλιψεϊ χετχρεο®. αωπδ λεμδ, ξλιψεϊ θας αΰξψιχδ δμθιπιϊ διεε 6 ΰηεζ ξλμμ δξλιψεϊ δτψξφαθιεϊ, ξψλζ εξζψη ΰιψετδ διεε 4 ΰηεζ ειωψΰμ διεεϊδ 4 ΰηεζ.
δξλιψεϊ δβμεαμιεϊ ωμ χετχρεο®, αξεπηι ξηιψ ξλιψδ μωεχ, δρϊλξε αψαςεο δψαιςι α-436 ξιμιεο γεμψ, βιγεμ ωμ 15 ΰηεζ αδωεεΰδ μψαςεο δξχαιμ α-2006. δξλιψεϊ αΰψδ"α φξηε α-13 ΰηεζ εδρϊλξε α-269 ξιμιεο γεμψ, αςεγ ωξλιψεϊ ξηευ μΰψδ"α (αιιηεγ αΰιψετδ) φξηε α-19 ΰηεζ εδρϊλξε α -166 ξιμιεο γεμψ. μωπϊ 2007, ξλιψεϊ βμεαμιεϊ ωμ χετχρεο®, αξεπηι ξηιψ ξλιψδ μωεχ, φξηε α-21 ΰηεζ, εδρϊλξε α-1,713 ξιμιεο γεμψ. ξλιψεϊ αΰψδ"α βγμε α-19 ΰηεζ, εδρϊλξε α-1,094 ξιμιεο γεμψ, εξλιψεϊ ξηευ μΰψδ"α φξηε α-24 ΰηεζ μ-619 ξιμιεο γεμψ.
δβιγεμ αξλιψεϊ ψαςεπιεϊ εωπϊιεϊ αΰψδ"α παςε ξβιγεμ αξρτψ δηεμιν δξωϊξωιν αχετχρεο® λξε βν ξδςμΰϊ ξηιψιν. αξδμκ 2007, χετχρεο® δξωικ μωτψ ΰϊ ξςξγε λξεφψ δξεαιμ αϊηεν δθιτεμ αθψωϊ πτεφδ. δβιγεμ αξλιψεϊ 2007 ξηευ μΰψδ"α, πας αςιχψ ξξλιψεϊ βαεδεϊ ιεϊψ αωεεχιν δΰιψετιιν δξψλζιιν (βψξπιδ, φψτϊ, αψιθπιδ, ρτψγ εΰιθμιδ), λξε βν αξγιπεϊ λβεο ψεριδ, αψζιμ εθεψχιδ.
ΰζιμχθ® ξξωικ μαρρ ΰϊ ξςξγε αιο δξεφψιν δχιιξιν μθιτεμ αξημϊ δτψχιπρεο αΰψδ"α εαΰιψετδ, ςν ξλιψεϊ δβμεαμιεϊ (αξεπηι ξηιψ ξλιψδ μωεχ) ωμ 34 ξιμιεο γεμψ αψαςεο δψαιςι, βιγεμ ωμ 79 ΰηεζ αδωεεΰδ μψαςεο δξχαιμ. δξλιψεϊ δωπϊιεϊ βγμε αιεϊψ ξτι ωπιιν αδωεεΰδ μ-2006, εδρϊλξε α-120 ξιμιεο γεμψ. ΰζιμχθ® ξΰεωψ λςϊ μωιξεω α- 29 ξγιπεϊ αδωεεΰδ μ-24 ξγιπεϊ αρεσ 2006.
δξλιψεϊ δβμεαμιεϊ ωμ ξεφψι πωιξδ δρϊλξε α-189 ξιμιεο γεμψ αψαςεο δψαιςι ωμ 2007, βιγεμ ωμ 18 ΰηεζ αδωεεΰδ μψαςεο δξχαιμ α-2006. δξλιψεϊ δωπϊιεϊ φξηε αλ-50 ΰηεζ ξ-498 ξιμιεο γεμψ α-2006 μ-742 ξιμιεο γεμψ α-2007. δβιγεμ πας αψεαε ξξλιψεϊ βαεδεϊ ωμProAir αΰψδ"α εξξλιψεϊ βαεδεϊ ωμ ξεφψι πωιξδ ΰηψιν αΰιψετδ (αξιεηγ ααψιθπιδ εφψτϊ).
ξλιψεϊ δλιξιδ (API) αψαςεο δψαιςι δρϊλξε α-463 ξιμιεο γεμψ, βιγεμ ωμ 65 ΰηεζ αδωεεΰδ μψαςεο δψαιςι ωμ 2006. ξλιψεϊ τπιξιεϊ μςρχι δτψξφαθιχδ ωμ θας βγμε α-150 ΰηεζ, αςεγ ωξλιψεϊ δλιξιδ μφγγιν ωμιωιιν αψαςεο ψαιςι δρϊλξε α-140 ξιμιεο γεμψ, ιψιγδ ωμ 8 ΰηεζ αδωεεΰδ μψαςεο δψαιςι ωμ 2006. αωπϊ 2007, λμμ ξλιψεϊ δλιξιδ βγμε α-10 ΰηεζ, μ-1,460 ξιμιεο γεμψ. δξλιψεϊ δτπιξιεϊ φξηε α-21 ΰηεζ, αςεγ ωξλιψεϊ λιξιδ μφγγιν ωμιωιιν δρϊλξε α-561 ξιμιεο γεμψ, ιψιγδ ωμ 4 ΰηεζ αδωεεΰδ μ-2006. δβιγεμ αξλιψεϊ τπιξιεϊ ξωχσ ξεφψιν ΰωψ δεωχε ςμ ιγι ΰιπθβψφιδ ΰπλιϊ αωπϊ 2007.
ωιςεψ δψεεη δβεμξι δβις μ-52.3 ΰηεζ αψαςεο δψαιςι ωμ 2007, βαεδ ξωξςεϊιϊ ξωιςεψ δψεεη δβεμξι ωμ 48.4 ΰηεζ ωπψων αψαςεο δξχαιμ α-2006. ωιςεψ δψεεη δβεμξι αψαςεο ζδ ξωχσ ϊξδιμ ηιεαι ωμ ξεφψιν, δλεμμ δωχδ ξωξςεϊιϊ ααμςγιεϊ αΰψδ"α, απερσ μξεφψιν δπξλψιν ϊηϊ δρλξιν ςν ωεϊτιν ωαδν ημεχϊ δψεεηιν (profit sharing) πψωξϊ λδεφΰεϊ ξλιψδ εωιεεχ. ωιςεψ δψεεη δβεμξι αψαςεο δψαιςι διδ γεξδ μωιςεψι δψεεη δβεμξι αωπι δψαςεπιν δχεγξιν εβαεδ ιεϊψ ξωιςεψ δψεεη δβεμξι δωπϊι ωμ 51.8 ΰηεζ.
δεφΰεϊ ξηχψ ετιϊεη (ξε"τ) πθε δρϊλξε αψαςεο δψαιςι α-168 ξιμιεο γεμψ ΰε 6.5 ΰηεζ ξδξλιψεϊ. αωπϊ 2007, δεφΰεϊ ξε"τ πθε δρϊλξε α-581 ξιμιεο γεμψ ΰε 6.2 ΰηεζ ξδξλιψεϊ, ςμιδ ξ-5.9 ΰηεζ α-2006. μχψΰϊ ρεσ δωπδ, δημιθδ θας μδβγιμ ΰϊ δεφΰεϊιδ ςμ ξηχψ ετιϊεη, αςιχψ ςμ ξε"τ βπψι. δημθδ ζε παςδ ξδαηιπδ δΰρθψθβιϊ ωδηαψδ ςψλδ α-2007.
δεφΰεϊ ξλιψδ, δπδμδ ελμμιεϊ (SG&A) δρϊλξε α-518 ξιμιεο γεμψ εα-1,901 ξιμιεο γεμψ μψαςεο δψαιςι εμωπϊ 2007, αδϊΰξδ. SG&A αψαςεο δψαιςι διε 20 ΰηεζ ξδξλιψεϊ, αγεξδ μωιςεψ δωπϊι, ΰαμ βαεδ ιεϊψ ξδωιςεψ δωπϊι ωμ 18.7 ΰηεζ α-2006. δβιγεμ αωιςεψ δεφΰεϊ δ-SG&A α-2007 διπε ϊεφΰδ ωμ ξλιψεϊ βγεμεϊ ιεϊψ ωμ ξεφψιν ξξεϊβιν λξε βν ξλιψεϊ βγεμεϊ ιεϊψ αωεεχιν βπψιιν ξξεϊβιν.
ωιςεψ δξρ μωπϊ 2007 δεΰ 17 ΰηεζ, αδωεεΰδ μωιςεψ ξρ ξεϊΰν ωμ 15 ΰηεζ μωπϊ 2006. ωιςεψ δξρ μψαςεο δψαιςι ωμ 2007 δεΰ 13 ΰηεζ ξδδλπρδ μτπι ξρ, αγεξδ μωιςεψ δξρ αψαςεο δξχαιμ αωπϊ 2006.
ϊζψιν δξζεξπιν ξτςιμεϊ ωεθτϊ αψαςεο δψαιςι ωμ 2007 δρϊλν α-545 ξιμιεο γεμψ εδαιΰ ΰϊ ρκ δξζεξπιν ωπεφψε ξτςιμεϊ ωεθτϊ αξδμκ δωπδ μ-1,813 ξιμιεο γεμψ. ϊζψιν δξζεξπιν δηετωι (μΰηψ ημεχϊ γιαιγπγ εδωχςεϊ αψλεω χαες) δρϊλν α-1,013 ξιμιεο γεμψ. ωεει ξζεξπιν επιιψεϊ ςψκ ρηιψιν μιεν 31 αγφξαψ, 2007, δρϊλν μ-3.3 ξμιΰψγ γεμψ.
δδεο δςφξι ωμ θας δρϊλν α-31 αγφξαψ, 2007, α- 13.7 ξμιΰψγ γεμψ, βιγεμ ωμ 805 ξιμιεο γεμψ μςεξϊ δ-30 αρτθξαψ, 2007. χψεα μωμιω ξδβιγεμ αδεο δςφξι ξωχσ δωτςδ ηιεαιϊ ωμ ωςψι ημιτιο.
πλεο μψαςεο δψαιςι ωμ 2007, ξρτψ δξπιεϊ μφεψκ ηιωεα δψεεη δπχι μξπιδ αγιμεμ ξμΰ, διπε 834 ξιμιεο ξπιεϊ. πλεο μ-31 αγφξαψ 2007 εδμΰδ, ξρτψ δξπιεϊ μφεψκ ηιωεα ξρτψ δξπιεϊ αγιμεμ ξμΰ ξεςψκ βν δεΰ α-837 ξιμιεο ξπιεϊ.
γιαιγπγ
γιψχθεψιεο δηαψδ, αιωιαϊε ξιεν 11 αταψεΰψ, 2008, δλψιζ ςμ ϊωμεν γιαιγπγ αξζεξο αβιο δψαςεο δψαιςι ωμ ωπϊ 2007, αωιςεψ ωμ 0.45 ω"η μξπιδ (λ-12.4 ρπθ ςμ τι ωςψ δγεμψ α-11 αταψεΰψ, 2008), αδωεεΰδ μ-0.40 ω"η μξπιδ αψαςεο δχεγν.
διεν δχεας ιδιδ α- 20 αταψεΰψ, 2008, ειεν δϊωμεν πχας μ-6 αξψυ, 2008. ωιςεψ δξρ ωιπελδ αξχεψ ιδιδ 16.5%.
τψθι ωιηϊ δεςιγδ
δπδμϊ θας ϊχιιν ωιηϊ εςιγδ αιεν ωμιωι, 12 αταψεΰψ, 2008, αωςδ 15:30 ωςεο ιωψΰμ (8:30 ωςεο πιε ιεψχ) ωαξδμλδ ϊρχεψ δπδμϊ δηαψδ ΰϊ ϊεφΰεϊ δψαςεο δψαιςι ωμ 2007 εδωπδ λεμδ. λξε λο ϊπϊο αωιηδ ϊηζιϊ μωπϊ 2008 ε-2009. πιϊο μδΰζιο μωιηδ γψκ ΰϊψ δΰιπθψπθ ωμ θας, αλϊεαϊ: www.tevapharm.com. ϊεκ 24 ωςεϊ μΰηψ ριεν δωιηδ, ωιγεψ ηεζψ ωμ δωιηδ ιδιδ ζξιο αΰϊψ δηαψδ. απερσ, πιϊο ιδιδ μδΰζιο μωιγεψ ηεζψ ωμ δωιηδ ςγ μιεν 19 αταψεΰψ, 2008 αηφεϊ (ωςεο πιε ιεψχ) ςμ-ιγι ηιεβ 877-660-6853 μξηιιβιν αϊεκ ΰψδ"α ε- 201-612-7415 μξηιιβιν ξηευ μΰψδ"α. χεγ δλπιρδ μωιγεψ δηεζψ διπε ηωαεο ξρτψ (account #) 3055 εϊε δζιδει (ID#) διπε 271953.
ΰεγεϊ θας
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ διπδ ηαψδ βμεαμιϊ ωαριρδ αιωψΰμ εΰηϊ ξ- 20δηαψεϊ δτψξφαθιεϊ δξεαιμεϊ αςεμν. θας, δξϊξηδ αιιφεψ ϊψετεϊ βπψιεϊ ειιηεγιεϊ ειιφεψ ηεξψιν τςιμιν μϊςωιδ δτψξφαθιϊ, διπδ δηαψδ δξεαιμδ αςεμν αϊηεν δβπψιχδ. μθας ΰϊψι ιιφεψ, ξηχψ, ωιεεχ εδτφδ αιωψΰμ, αφτεο εαξψλζ ΰξψιχδ εαΰιψετδ. ιεϊψ ξ- 80% ξξλιψεϊιδ ωμ δχαεφδ δο μφτεο ΰξψιχδ εΰιψετδ.
μδμο δρςισ διγες αΰψδ"α λ- Safe Harbor απερηε δΰπβμι εΰωψ ξθψϊε μδβο ςμ δηαψδ, ςτ"ι δγιο δΰξψιχΰι:
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: whether and when the proposed acquisition of CoGenesys will be consummated, whether and when Teva will obtain HSR approval for the acquisition and any conditions that could be imposed in connection with such approval, Teva's ability to rapidly integrate CoGenesys' operations with its own operations, the diversion of management time on merger-related issues, and Teva and CoGenesys' ability to successfully develop and commercialize biopharmaceutical products, Teva's ability to accurately predict future market conditions, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra®, Neurontin®, Lotrel® Famvir®, and Protonix®, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, the effects of competition on our innovative products, especially Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: whether and when the proposed acquisition of CoGenesys will be consummated, whether and when Teva will obtain HSR approval for the acquisition and any conditions that could be imposed in connection with such approval, Teva's ability to rapidly integrate CoGenesys' operations with its own operations, the diversion of management time on merger-related issues, and Teva and CoGenesys' ability to successfully develop and commercialize biopharmaceutical products, Teva's ability to accurately predict future market conditions, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra®, Neurontin®, Lotrel® Famvir®, and Protonix®, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, the effects of competition on our innovative products, especially Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
| © 1999 - 2008 λμ δζλειεϊ ωξεψεϊ μθας | ϊπΰι ωιξεω αΰϊψ | ξτϊ δΰϊψ |